Cerapedics’ PearlMatrix P-15 peptide enhanced bone graft for lumbar spinal fusion earned FDA premarket approval, the company said June 23.
The FDA granted it a Class III drug-device combination product for single-level transforaminal lumbar interbody fusion in adults for degenerative disc disease, according to a news release. PearlMatrix P-15 is the only bone graft of its kind proven to accelerate bone growth in lumbar fusions.
In a U.S. trial the bone graft was found to have substantially higher fusion rates at 24 months and more than twice as many patients fused at six months compared to a local autograft.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
